Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): N,N-Dimethyl-5-methoxytryptamine

            Therapeutic Area: Psychiatry/Psychology Product Name: GH001

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: RA Capital

            Deal Size: $125.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing April 13, 2021

            Details:

            GH Research will use the proceeds to support further clinical development of GH001 (5-MeO-DMT) in Treatment-Resistant Depression (TRD) and to advance GH001 into further clinical development in additional psychiatric and neurological disorders.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): N,N-Dimethyl-5-methoxytryptamine

            Therapeutic Area: Psychiatry/Psychology Product Name: GH001

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 19, 2020

            Details:

            GH001 has the potential to offer an ultra-rapid clearance of symptoms with long-term sustained remission after a single administration session. In the completed Phase 1 healthy volunteer study (GH001-HV-101), GH001 was safe and well-tolerated at the investigated dose levels.